This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 7
  • /
  • MAA for FYB 201, biosimilar to Lucentis is filed a...

MAA for FYB 201, biosimilar to Lucentis is filed at EMA .- Formycon AG + Bioeq AG.

Read time: 1 mins
Published:1st Jul 2021
Formycon AG and its license partner Bioeq AG announce that the marketing authorization application (MAA) for FYB 201, Formycon’s biosimilar candidate to Lucentis (ranibizumab), has been submitted to the European Medicines Agency (EMA).Lucentisis used in the treatment of neovascular (wet) macular degeneration and other serious eye diseases.

It inhibits vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.

The commercialization of FYB 201 in Europe will be performed by Teva Pharmaceutical Industries Ltd., which has acquired the distribution rights under an exclusive strategic partnership from Bioeq AG.

Condition: Age Related Macular Degeneration
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.